Drug Trial Radar · NCT05018286
Open-label Extension Trial to Evaluate the Long-term Safety of Apraglutide in Short Bowel Syndrome.
Last checked: Nov 19, 2026Latest source record: Jul 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
158
Actual
Start
Jul 13, 2021
Primary completion
Oct 30, 2027
Study completion Oct 30, 2027
Sponsor
- Lead sponsor
- VectivBio AGIndustry
- Sponsor type
- Industry
- First posted
- Aug 24, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the trial is to assess long-term safety and tolerability of apraglutide in subjects with SBS-IF.
Conditions
- Short Bowel Syndrome
Interventions
ApraglutideDrug
Apraglutide is a synthetic peptide analogue of GLP-2 under development for treatment of SBS-IF, which acts as a full agonist at the GLP-2 receptor with in vitro potency and selectivity comparable with native GLP-2
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse events (AE)Time frame: From baseline to week 208
- Clinical chemistryTime frame: From baseline to week 208
- HematologyTime frame: From baseline to week 208
- HemostasisTime frame: From baseline to week 104
- UrinalysisTime frame: From baseline to week 208
- Occurrence of clinically relevant changes in vital signsTime frame: From baseline to week 208
- Occurrence of clinically relevant changes in electrocardiogramTime frame: From baseline to week 208
Locations
66 sites in 18 countries. Site status is shown where the registry gives one.
Ronald Reagan UCLA Medical Center
Los Angeles, California
Gastroenterology Group of Naples
Naples, Florida
Northwestern University - Chicago
Chicago, Illinois
Henry Ford Health System
Detroit, Michigan
Mayo Clinic - Rochester
Rochester, Minnesota
University of Nebraska Medical Center
Omaha, Nebraska
Mount Sinai Medical Center
New York, New York
Duke University Medical Center
Durham, North Carolina
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio
Cleveland Clinic Foundation
Cleveland, Ohio
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania
Vanderbilt University Medical Center
Nashville, Tennessee
University of Washington Medical Center
Seattle, Washington
University Hospital Fundacion Favaloro
Buenos Aires, Argentina
University Hospital Brussels
Brussels, Belgium
UZ Leuven
Leuven, Belgium
University Hospital Brno
Brno, Czechia
University Hospital Hradec Kralove
Hradec Králové, Czechia
Hospital Novy Jicin
Nový Jičín, Czechia
University Hospital Plzen
Pilsen, Czechia
University Hospital Kralovske Vinohrady
Prague, Czechia
General University Hospital in Prague
Prague, Czechia
Rigshospitalet - University Hospital Copenhagen, Department of Intestinal Failure and Liver Diseases
Copenhagen, Denmark
Beaujon Hospital
Clichy, France
South Lyon Hospital Center
Lyon, France
Nantes University Hospital Center - Hotel Dieu Hospital
Nantes, France
Nice University Hospital Center - Archet 1 Hospital
Nice, France
Hôpital Haut-Lévèque
Pessac, France
Brabois Adults Hospital
Vandœuvre-lès-Nancy, France
Charite - University Hospital Berlin
Berlin, Germany
University Hospital Bonn
Bonn, Germany
Asklepios Clinic St. Georg
Hamburg, Germany
University Hospital Heidelberg
Heidelberg, Germany
University Hospital Muenster
Münster, Germany
Szent Imre University Teaching Hospital, Department of Gastroenterology
Budapest, Hungary
Central Hospital of Northern Pest - Military Hospital
Budapest, Hungary
Semmelweis University
Budapest, Hungary
University of Szeged
Szeged, Hungary
Rambam Health Care Campus, Institute of Gastroenterology
Haifa, Israel
Chaim Sheba Medical Center
Tel HaShomer, Israel
Showing 40 of 66 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.